In the specification:

Please add the following paragraph on page 1, line 3:

--This application is a continuation application of U.S Application Serial No. 09/603,153, filed June 23, 2000, now U.S. Patent No. 6,497,874, which in turn claims priority from U.S. Application Serial No. 09/117,798, filed August 6, 1998, now abandoned, which was the national stage of International Application number PCT/SE97/00172, filed February 5, 1997, which claims priority from Swedish Application No. 9600434-6, filed February 6, 1996, the contents of each of which application is herein specifically incorporated by reference in its entirety.--

Please replace "CLAIMS" with "We claim" on page 29, line 1.

Please add the following Abstract on separate page 21, at line 1.

ABSTRACT

The present invention relates to bacteriophages for use in the treatment or prophylaxis of bacterial infections, especially mucosal bacterial infections such as *Helicobacter pylori* infections. In particular, it relates to modified filamentous bacteriophages, e.g. M13 phages, for such use, which bacteriophages present at their surface a recombinant protein comprising: (i) a first component derived from a bacteriophage surface protein; and (ii) a second component comprising variable region sequences of an antibody to provide a bacterial antigen binding site, said second component rendering said bacteriophage capable of binding to and thereby inhibiting growth of bacterial cells involved in the etiology of said infection.